The present disclosure relates to a transportation device for transporting a medicament, the transportation device comprising:
a body comprising a storage compartment sized to receive a medicament container,
a motion sensor attached to the body and operable to generate an electric motion signal being indicative of a motion of the body,
a support inside the storage compartment and provided with at least one actuator, the support further comprising a holder for the medicament container, wherein the holder is movable relative to the body by the actuator,
a controller connected to the motion sensor and connected to the at least one actuator, wherein the controller is operable to control operation of the at least one actuator on the basis of the motion signal obtained from the motion sensor.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
The present invention relates to a method for tailing in vitro transcribed (IVT) messenger RNA (mRNA) comprising a modified ribonucleotide, said method comprising adding the IVT mRNA to a tailing polymerase in a reaction buffer comprising 30 mM or less of an alkali metal salt and 5 mM or more of a reducing agent.
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I): or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II): or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III): or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV): or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I): or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II): or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III): or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV): or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
4.
COMPOSITIONS AND METHODS FOR TREATING LATE-ONSET POMPE DISEASE
The present application provides methods of treating late-onset Pompe disease (LOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa.
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A medicament delivery device is described. The device includes a body having proximal and distal ends defining a longitudinal direction; a needle for injecting medicament into a user and configured to be arranged in an injecting position in which the needle protrudes from the distal end of the body; a cap moveable along the longitudinal direction to be arrangeable in a capped position in which the cap conceals the distal end of the body, and an uncapped position in which at least a portion of the cap is spaced apart from the distal end; and a blocking element. When the cap is in the uncapped position, the blocking element is arrangeable in a first state in which movement of the cap from the uncapped position into the capped position is permitted, and a second state in which movement of the cap from the uncapped position into the capped position is prevented.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
This specification relates to systems and methods for identifying locations of potential patients and/or healthcare providers from geofencing data using machine-learned models. According to a first aspect of this specification, there is described a computer implemented method of identifying potential disease diagnoses and/or healthcare providers. The method comprises: receiving geofencing data from one or more healthcare locations, the geofencing data relating to the disease comprising one or more impressions made at the healthcare location and/or one or more clicks made at the healthcare location; extracting, for each of a plurality of entities, a plurality of features from the geofencing data, wherein each entity is associated with a respective healthcare location in the one or more healthcare locations.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNAs) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w/w) than the mRNA encoding the influenza B virus, and methods of eliciting an immune response by administering said compositions. In particular, the disclosures relate to mRNA encoding these antigens formulated in a lipid nanoparticle (LNP).
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present disclosure relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.
The present disclosure relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Provided herein is a fusion protein comprising a messenger RNA (mRNA) capping enzyme polypeptide linked to a Fh8 polypeptide or fragment thereof. Also provided are methods of preparing a mRNA comprising the step of capping using the capping enzymes described herein.
Provided herein are compositions and methods for identifying the cell-type origin of cells based on RNA-sequencing (RNA-seq) data. The methods provided herein can include steps of receiving a plurality of sequencing read counts; providing a set of cell types to be detected and an associated gene set G for each cell type, such that each gene set G comprises a plurality of genes g; scoring the sequencing read counts to generate an assignment score; and assigning each cell of the plurality of cells to a cell-type with the highest assignment score to identify the cell-type origin of each cell. The methods can be implemented using, for example, a computer system.
Methods and systems are provided to determine efficacy of a medical treatment by monitoring biomarkers of a patient undergoing the medical treatment. The monitoring is performed by sensors that are attached to the patient while the patient is performing his/her normal life. For example, the sensors can be worn similar to a watch, a headband, a belt, etc.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
16.
COMPOUNDS, CONSTRUCTS AND COMPOSITIONS TARGETING TNF AND OX40L FOR USE IN THE TREATMENT OF TYPE 1 DIABETES
The present technology provides a novel treatment for protecting beta cells from an immune response, particularly for preventing the onset and/or the progress of Type 1 diabetes (T1D) using an antagonist of OX40L and an antagonist of TNF.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A drug delivery device includes a housing, a blocking feature rotationally secured relative to the housing, a drive unit, a rod operatively coupled to the drive unit and arranged to move distally relative to the housing when the rod is released, and a movable trigger member. The rod is rotatable relative to the housing and has an unprimed state and a primed state. In the unprimed state, the blocking feature is arranged to block a rotation of the rod into the release position, and in the primed state, a trigger member feature is arranged to block rotation of the rod into the release position. The trigger member is arranged to move relative to the housing to release the rod. To switch from the unprimed state into the primed state, the trigger member moves and a movement is converted into an axial movement of the rod relative to the blocking feature.
The present technology relates to a novel cleaning method for chromatography media and/or supporting equipment comprising treatment with a novel cleaning solution comprising sodium hydroxide and hexylene glycol.
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
The present technology relates to a novel sanitization method for chromatography media and supporting equipment comprising treatment with a sanitization/sterilization solution comprising acetic acid and hexylene glycol.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Measuring instruments; Measuring apparatus; Signalling apparatus and instruments; Checking (supervision) apparatus and instruments; Data processing equipment; Computer programs, recorded; Downloadable applications for use with mobile devices; Educational mobile applications; Web application software; Artificial intelligence and machine learning software; Artificial intelligence software for healthcare; Training software; Educational software; Machine learning software for healthcare; Computer software platforms; Computer programs, downloadable; Virtual reality software for medical teaching; Downloadable mobile applications for the management of data; Downloadable mobile applications for the management of information; Health monitoring software; Downloadable computer software for the management of data; Downloadable computer software for remote monitoring and analysis; Computer software applications, downloadable; Downloadable software applications; Computer application software for use with wearable computer devices; Software as a medical device [SaMD], downloadable; Application software for wireless devices; Apparatus for the transmission of data; Sensors, detectors and monitoring equipment; Microprocessor cards; Memory boards; Computer software, recorded. Medical apparatus and instruments; Injection instruments without needles; Injection device for pharmaceuticals; Hypodermic injectors; Inoculating apparatus; Apparatus for drug administration; Apparatus for administering pharmaceuticals; Hypodermic syringes for use in administering injection substances; Automatic medical apparatus for dosing humans by injection; Automatic medical apparatus for dosing animals by injection; Implantable subcutaneous drug delivery devices; Autoinjectors for the administration of pharmaceutical preparations; Dosage dispensers for medical use; Syringes in the nature of pens; Injectors for medical purposes; Medication injectors; Diabetic monitoring apparatus; Medical diagnostic, examination, and monitoring equipment; Medical test kits for diabetes monitoring for home use; Medical instruments for therapeutic drug monitoring; Medical instruments for recording physiological data. Medical services; Medical services in the field of treatment of chronic pain; Providing medical information; Telemedicine services; Providing information to patients in the field of administering medications; Providing information relating to medical services; Providing information via the Internet in the field of diabetes; Providing medical support in the monitoring of patients receiving medical treatments; Medical services in the field of diabetes; Individual medical counseling services provided to patients; Medical care and analysis services relating to patient treatment; Medical information services provided via the Internet; Medical information retrieval services; Consultancy and information services relating to medical products; Remote monitoring of medical data for medical diagnosis and treatment; Monitoring of patients; Providing online medical record services other than dentistry; Medical diagnostic services; Pathological testing for diagnostic and treatment purposes; Medical tele-reporting [medical services]; Medical services for the diagnosis of conditions of the human body.
21.
Systems and Methods for Medication and Disease Management and Patient Notification
A non-transitory computer readable storage medium includes instructions that, when executed by a computer, cause the computer to execute a program for managing a user's medical condition or treatment. The program defines a notification scheme for creating notifications associated with the user's medical condition or treatment. The system generates different types of notifications based on the occurrence of first, second, and third-level trigger events. These notifications are displayed on a graphical user interface provided by the program or an operating system of a user device. The content of the notifications can vary depending on the user's experience level. The system can also start a timer for allowing medicament in a medicament delivery device to reach room temperature in response to user interaction with a specific notification.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.
Provided are lipid-based systems, compositions, and methods of making and using the same. The lipid-based systems contain lipid nanoparticles and specifically formulated liposomes to reduce or prevent lipid nanoparticle clearance in vivo in subjects towards LNPs or components thereof.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
26.
AAV GENOMES ENCODING ENGINEERED HUMAN FRATAXIN TRANSGENE
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a disorder-related polypeptide. Also provided are methods to treat Friedreich's ataxia. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a disorder-related polypeptide in an individual in need thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A computer-implemented method for performing image registration of a plurality of images of a subject, the method comprising: receiving a first image of a subject and a second image of the subject; performing a first image registration to register the first image and the second image; receiving parameters of a bounding shape identifying a region of interest of the registered first image or the registered second image; generating a first cropped image of the registered first image and a second cropped image of the registered second image based on the parameters of the bounding shape; and performing a second image registration to register the first cropped image and the second cropped image.
The invention provides ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to target cells, such as immune cells and hematopoietic stem cells, and methods of making and using, such lipids and targeted lipid nanoparticles.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07D 317/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
29.
SYSTEMS AND METHODS FOR PREDICTING BIOLOGICAL RESPONSES
Systems and methods can apply machine learning techniques to predict biological responses. One of the methods is performed by at least one processor executing executable logic including at least one machine learning model trained to predict biological responses. The method includes receiving first sequence data of a first molecular sequence, receiving second sequence data of a second molecular sequence, and predicting a biological response for the second molecular sequence based at least partly on the received first and second sequence data.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Provided herein are lipid nanoparticles (LNPs) comprising an ionizable or cationic lipid, a helper lipid, a structural lipid, and a stealth lipid. The LNPs provided herein can be useful for delivery and expression of mRNA and encoded protein and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
31.
DIANHYDROHEXITOL BASED IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY
e.g.e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Measuring instruments; Measuring apparatus; Signalling apparatus and instruments; Checking (supervision) apparatus and instruments; Data processing equipment; Computer programs, recorded; Downloadable applications for use with mobile devices; Educational mobile applications; Web application software; Artificial intelligence and machine learning software; Artificial intelligence software for healthcare; Training software; Educational software; Machine learning software for healthcare; Computer software platforms; Computer programs, downloadable; Virtual reality software for medical teaching; Downloadable mobile applications for the management of data; Downloadable mobile applications for the management of information; Health monitoring software; Downloadable computer software for the management of data; Downloadable computer software for remote monitoring and analysis; Computer software applications, downloadable; Downloadable software applications; Computer application software for use with wearable computer devices; Software as a medical device [SaMD], downloadable; Application software for wireless devices; Apparatus for the transmission of data; Sensors, detectors and monitoring equipment; Microprocessor cards; Memory boards; Computer software, recorded. Medical apparatus and instruments; Injection instruments without needles; Injection device for pharmaceuticals; Hypodermic injectors; Inoculating apparatus; Apparatus for drug administration; Apparatus for administering pharmaceuticals; Hypodermic syringes for use in administering injection substances; Automatic medical apparatus for dosing humans by injection; Automatic medical apparatus for dosing animals by injection; Implantable subcutaneous drug delivery devices; Autoinjectors for the administration of pharmaceutical preparations; Dosage dispensers for medical use; Syringes in the nature of pens; Injectors for medical purposes; Medication injectors; Diabetic monitoring apparatus; Medical diagnostic, examination, and monitoring equipment; Medical test kits for diabetes monitoring for home use; Medical instruments for therapeutic drug monitoring; Medical instruments for recording physiological data. Medical services; Medical services in the field of treatment of chronic pain; Providing medical information; Telemedicine services; Providing information to patients in the field of administering medications; Providing information relating to medical services; Providing information via the Internet in the field of diabetes; Providing medical support in the monitoring of patients receiving medical treatments; Medical services in the field of diabetes; Individual medical counseling services provided to patients; Medical care and analysis services relating to patient treatment; Medical information services provided via the Internet; Medical information retrieval services; Consultancy and information services relating to medical products; Remote monitoring of medical data for medical diagnosis and treatment; Monitoring of patients; Providing online medical record services other than dentistry; Medical diagnostic services; Pathological testing for diagnostic and treatment purposes; Medical tele-reporting [medical services]; Medical services for the diagnosis of conditions of the human body.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of immunological, immune, inflammatory, respiratory, and liver diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare immunological diseases, immune system-related conditions, inflammatory, respiratory, and liver diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the prevention and treatment
of cardiovascular diseases and central nervous system
diseases; pharmaceutical preparations for treatment of
cancer, thrombosis and respiratory diseases; pharmaceutical
preparations for the treatment of rare diseases,
particularly lysosomal storage disorders and autosomal
dominant polycystic kidney disease; pharmaceutical
preparations for the prevention and treatment of infectious
diseases, namely, bacterial and viral infections.
The present disclosure relates to a cartridge packaging (1) with an outer shell and at least one cartridge (2) filled with a liquid drug for use in a pen type drug delivery device. The shell is a packaging with a bottom wall (3), two side walls (4), a front wall (5), a back wall (6), a top wall (7) and a closing flap (8) made of a single piece blank (10) of e.g. cardboard. The shell further comprises at least one tear-off strip (9) hinged to at least the closing flap (8) by one or more weakened lines (11).
The present disclosure relates to a cartridge packaging (1) with an outer shell (3) closed in a tamper proof manner and comprising at least one cartridge (2) filled with a liquid drug for use in a pen type drug delivery device. The shell (3) is a flow wrapped film made of a flexible low-density polyethylene (LDPE) material tube which is heat sealed at two opposite ends. Optionally, a secondary packaging box (8) may be provided housing several shells (3) with cartridges (2).
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
B65D 5/50 - Internal supporting or protecting elements for contents
B65D 71/66 - Tray-like packaging elements provided with handles for storage or transport of a plurality of articles formed by folding one blank into a tubular element, having upper wall portions provided with openings, through which the articles extend for holding only one row of articles
B65D 75/38 - Articles or materials enclosed in two or more wrappers disposed one inside the other
B65D 75/40 - Packages formed by enclosing successive articles, or increments of material, in webs, e.g. folded or tubular webs, or by subdividing tubes filled with liquid, semi-liquid, or plastic materials
B65D 75/44 - Individual packages cut from webs or tubes
B65D 75/46 - Individual packages cut from webs or tubes containing articles
B65D 75/52 - Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers Details
B65D 75/58 - Opening or contents-removing devices added or incorporated during package manufacture
B65D 75/66 - Inserted or applied tearing-strings or like flexible elements
B65D 77/02 - Wrapped articles enclosed in rigid or semi-rigid containers
B65D 77/04 - Articles or materials enclosed in two or more containers disposed one within another
B65D 5/54 - Lines of weakness to facilitate opening of container or dividing it into separate parts by cutting or tearing
B65D 5/42 - Details of containers or of foldable or erectable container blanks
B65D 5/02 - Rigid or semi-rigid containers of polygonal cross-section, e.g. boxes, cartons or trays, formed by folding or erecting one or more blanks made of paper by folding or erecting a single blank to form a tubular body with or without subsequent folding operations, or the addition of separate elements, to close the ends of the body
B65D 77/00 - Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags
37.
METHODS AND SYSTEMS FOR PERSONALIZED INTERACTION WITH CUSTOMERS
A method (100) or system (200) for generating and providing a recommendation regarding interaction with healthcare professionals, comprising: receiving (110) information about the plurality of healthcare professionals; determining (120) which of the plurality of healthcare professionals to interact with; determining (130) which interaction channel(s) to use to interact with the healthcare professionals; analyzing (150) content usage for the healthcare professionals and determining (160) which content is most effective for the healthcare professionals; determining (170) a next best approved content for the healthcare professionals; generating (180) a next best interaction recommendation for the healthcare professionals, comprising at least a recommended which of the plurality of healthcare professionals to interact with, the next best approved content to provide to the healthcare professionals, and which of the plurality of different interaction channels to use; and providing (190) the generated next best interaction recommendation.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
38.
HOLD ASSISTANCE DEVICE FOR USE WITH A MEDICAMENT DELIVERY DEVICE
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes a body that includes: a receiving volume for receiving a medicament delivery device; a proximal portion comprising a proximal end of the body; a distal portion comprising a distal end of the body, the proximal and distal ends defining an axial direction; and a connecting portion arranged between the proximal and distal portions, wherein the connecting portion is configured to flex into the receiving volume in a direction generally normal to the axial direction, causing the proximal portion to move axially relative to the distal portion.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
39.
HOLD ASSISTANCE DEVICE FOR USE WITH A MEDICAMENT DELIVERY DEVICE
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes: a housing configured to be fixedly coupled to a medicament delivery device, the housing comprising: a proximal end and a distal end defining an axial direction, and an inclined surface angled relative to the axial direction; a blocking element moveable along the inclined surface; and an actuation element moveable relative to the housing and arrangeable in an activated position in which the actuation element applies an activation force to the blocking element in a direction towards the distal end, such that movement of the actuation element into the activated position causes the blocking element to move against the inclined surface towards the distal end and to exert a clamping force generally normal to the axial direction.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
40.
HOLD ASSISTANCE DEVICE FOR USE WITH A MEDICAMENT DELIVERY DEVICE
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes: a housing configured to be coupled to a medicament delivery device; a chamber for containing air, the chamber having a proximal end and a distal end; and a piston movable within the chamber between the proximal and distal ends of the chamber, wherein the piston is arrangeable in an activated position inside the chamber in which the piston is arranged proximate to the proximal end of the chamber such that the chamber is at least partially evacuated of air and movement of the piston towards the distal end of the chamber is resisted by a vacuum force.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The present invention relates to a method for producing (S)-amlodipine succinate comprising reacting (S)-amlodipine (D)-hemitartrate or a solvate thereof with a first base in the presence of a two-phase solvent system comprising a first non-polar organic solvent and water to produce (S)-amlodipine base, removing the water layer, and reacting (S)-amlodipine base with succinic acid to produce (S)-amlodipine succinate. The present invention also relates to a formulation comprising (S)-amlodipine succinate.
Disclosed is an audible indicator, preferably for a drug delivery device, comprising:
At least two wing shaped sections,
A plastically deformed bend arranged between the at least two wing shaped sections,
wherein the audible indicator comprises an elastically deformed bend or is configured to be deflected to form an elastically deformed bend,
wherein the elastically deformed bend is arranged oblique to the plastically deformed bend, and
At least two lateral tabs extending from outer edges of the two wing shaped sections respectively,
wherein the lateral tabs are configured to position the audible indicator within a device.
Drug delivery device for delivering a dose of medicament in a dose dispensing process, the drug delivery device being configured to have a first state in which a plunger rod and the plunger stopper are not visible through a drug window; and a second state in which the plunger stopper is not visible through the drug window and the plunger rod is visible through the drug window, wherein the plunger rod is provided with at least one feedback element, the feedback element is configured to be visible through the drug window in the second state.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
The present disclosure provides multispecific (e.g., bispecific) binding proteins with binding specificity to TNFR superfamily receptor (TNFRSF) and an immune checkpoint protein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This specification relates to predicting medical events based on medical records using machine learning. According to a first aspect of this specification, there is described a computer implemented method, comprising: inputting, into a machine-learning language model, a set of input data relating to a subject, the input data comprising: a plurality of medical record tokens, wherein a plurality of the medical record tokens each indicate a respective medical event for the subject within a first time window; and a plurality of time tokens, each time token corresponding to a respective medical record token and indicating a respective time associated with the medical record token. The method further comprises processing, by the machine-learning language model, the set of input data to generate a set of output data, the set of output data comprising data indicative of a prediction of a medical event for the subject within a second time window subsequent to the first time window. The method further comprises generating, based on the set of input data and the prediction of a medical event, an attribution score for each of a plurality of the input medical record tokens using an integrated gradients method, wherein the attribution score for a token is indicative of an amount that said token contributed to the prediction of the medical event.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure relates to a pen injector carry case (10, 20, 30) suitable for storing a drug delivery device (1). The carry case (10, 20, 30) comprises a first compartment (13, 23, 33) configured to receive a pen type a drug delivery device (1) and a second compartment (14, 24, 34) configured to receive accessories (2, 3) for the pen type a drug delivery device (1). The carry case (10, 20, 30) is made from two sheets or panels (11, 21, 31, 12, 22, 32) of a high-density polyethylene (HDPE) material that are connected together along seams (15, 25, 35, 16, 26, 36).
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
The present disclosure relates to a pen injector carry case (10) suitable for storing ac- cessories (2, 3) of a drug delivery device (1). The carry case (10) comprises an elongate body (11) with at least one compartment (13, 14) configured to receive accessories (2, 3) for the pen type a drug delivery device (1). The body (11) is a single-piece component part made of polypropylene (PP) or of high-density polyethylene (HDPE) and comprises a receiving channel (16) with a locking element configured to releasably fasten a pocket clip (4) the pen type a drug delivery device (1).
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
The present disclosure provides a method for degrading a target protein, comprising: contacting an IL-2Rβγ positive cell with a multispecific binding protein, wherein the multispecific binding protein comprises: a) a first cell surface binding moiety that specifically binds to a CD122 (IL-2Rβ) subunit and/or a CD132 (IL-2Rγ) subunit, on the surface of the IL-2Rβγ positive cell, wherein the first cell surface binding moiety comprises at least one immunoglobulin domain or a fragment thereof; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein specific binding of the multispecific binding protein to the IL-2Rβ subunit and/or the IL-2Rγ subunit facilitates the internalization of the target protein into the IL-2Rβγ positive cell. The present disclosure also provides multispecific binding proteins and methods of using the multispecific binding proteins to treat disease.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A hold assistance device for use with a medicament delivery device including a moveable needle cover. The hold assistance device comprises a housing coupled to a medicament delivery device, the housing comprising a proximal end and a distal end defining an axis between the proximal and distal ends; a holding element coupled to the housing and moveable relative to the housing in a direction substantially normal to the axis of the housing between a disengaged position and an engaged position; wherein the holding element is disposed outwardly from the axis in the disengaged position and is disposed inwardly towards the axis in the engaged position configured in the engaged position such that the holding element can engage with an aperture or recess in a needle cover of a medicament delivery device when the hold assistance device is coupled thereto, to resist movement of the needle cover relative to the housing.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A medicament delivery device for injecting a medicament is described. The medicament delivery device comprises a housing having a proximal end and a distal end, the housing being configured to receive a medicament container. A plunger is moveable in a longitudinal direction within the housing for dispensing medicament from the medicament container when the medicament container is received within the housing. A plunger drive magnet is operatively coupled to the housing, and the plunger drive magnet is configured to provide a magnetic field. A component is configured to magnetically interact with the magnetic field of the plunger drive magnet so as to cause a force to be exerted on the plunger for causing the plunger to move in the longitudinal direction.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A hold assistance device for use with a medicament delivery device is described. The hold assistance device includes: a first support configured to be fixedly coupled to a main body of a medicament delivery device, wherein the first support comprises a first attraction component; and a second support moveable relative to the first support between an initial position and a hold position and configured to be fixedly coupled to a needle cover of the medicament delivery device, wherein the second support includes a second attraction component, and wherein at least one of the first attraction component and the second attraction component is a magnet, and the other of the first attraction component and the second attraction component is a magnet or a ferromagnetic material; and wherein movement of the second support towards the hold position moves the second attraction component towards the first attraction component.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Préparations pharmaceutiques pour le traitement et la prévention des maladies et troubles immunologiques, immunitaires, inflammatoires, respiratoires et hépatologiques; préparations pharmaceutiques pour le traitement et la prévention de maladies immunologiques rares, liées au système immunitaire, maladies et troubles immunitaires, inflammatoires, respiratoires et hépatologiques; préparations pharmaceutiques pour les maladies et troubles rares.
53.
NEUTRALIZING ANTI-AMYLOID BETA ANTIBODIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Binding polypeptides (e.g., antibodies and antigen-binding fragments thereof) that specifically bind one or more species of soluble, AD brain-derived synaptotoxic amyloid beta (Aβ) without binding to classical monomeric, protofibrillar or fibrillar Aβ, are provided. Pharmaceutical compositions comprising binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of making binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of treating Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic A are provided. Methods of reducing one or more symptoms of Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic are provided.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The present application relates to the field of biomedical detection, and particularly to a capture probe, a familial chylomicronemia syndrome detection kit containing the same, and use thereof. The present application aims to detect FCS-related gene mutations stably and accurately, and to provide a more convenient and accurate FCS detection method for clinical practice. It is of great significance for the clinical diagnosis and treatment of FCS.
The disclosure provides methods of purifying adeno-associated virus (AAV) particles by introducing a flocculant step into a large scale a manufacturing process, thereby improving AAV particle purity and yield.
Compositions and methods for treating macular degeneration are disclosed. The methods utilize gene delivery to human eyes of soluble Flt-1 receptors, as well fusion proteins including a soluble Flt-1 receptor.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/00 - Medicinal preparations characterised by special physical form
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
H02J 7/02 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
A method for assembling an assembly for a drug delivery device includes guiding a container holder with a medicament container arranged in the container holder distally relative to a device body until the medicament container engages a deformable engagement structure. The method includes moving the container holder distally relative to the device body, the engagement structure, and the medicament container, towards an end position of the container holder relative to the device body. The method includes moving the container holder and the medicament container distally relative to the device body and the engagement structure into the end position, thereby deforming the engagement structure.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
59.
SYSTEMS AND METHODS FOR MODELING THROMBIN-ANTITHROMBIN
The present disclosure provides methods and systems for modeling, simulating, and treating hemophilia. The methods and systems disclosed herein include a quantitative systems pharmacology (QSP) model to predict features of thrombin generation in people with hemophila A and people with hemophilia B in the context of antithrombin (AT) lowering.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
C07D 453/00 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
C07D 455/02 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
The present invention provides bacterial strains with modifications in the tolC and/or fhuA genes and methods of introducing those modifications in bacterial cells. The modifications result in increased resistance of the bacterial strains against bacteriophages, such as the TLS phage, the T1 phage and/or the T5 phage.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
The present disclosure provides methods of producing in a single cell a mixed population of recombinant adeno-associated viruses for expressing two or more transgenes and methods of producing recombinant adeno-associated viruses containing self-complementary genomes. Also provided are methods of treating diseases using the rAAV compositions produced herein.
The disclosure relates to compound of formula (I)
The disclosure relates to compound of formula (I)
wherein R1 represents a phenyl or a monocyclic heteroaryl, which is optionally substituted by one, two or three R3; R2 represents an aryl or a heteroaryl, which is optionally substituted by one, two or three R6; each R3 is independently chosen from a halogen, a cyano, a (C1-C4)alkyl group or a (C1-C4)alkoxy group; R4 and R5 are independently chosen from a halogen, a (C1-C4)alkyl group, a (C1-C4)alkoxy group, or R4 and R5 form together a (C1-C4)alkylene bridge; m and s are independently 0 or 1; p, q, r and t are independently 0 or 1; each R6 is independently selected from halogen, cyano, a —NH2 group, —OH, a (C1-C4)alkyl group, —CF3, —C(O)NH2, a —C(O)NH—(C1-C4)alkyl group, —C(O)OH, a —C(O)O—(C1-C4)alkyl group, —SO2NH2, a (C1-C4)alkoxy group, a —O—(C1-C4)alkylene-(C3-C6)cycloalkyl group, a —O—(C3-C6)cycloalkyl group, a —O—(C3-C6)heterocycloalkyl group, a (C3-C6)heterocycloalkyl group, a heteroaryl group and oxo; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
The disclosure relates to compound of formula (I)
wherein R1 represents a phenyl or a monocyclic heteroaryl, which is optionally substituted by one, two or three R3; R2 represents an aryl or a heteroaryl, which is optionally substituted by one, two or three R6; each R3 is independently chosen from a halogen, a cyano, a (C1-C4)alkyl group or a (C1-C4)alkoxy group; R4 and R5 are independently chosen from a halogen, a (C1-C4)alkyl group, a (C1-C4)alkoxy group, or R4 and R5 form together a (C1-C4)alkylene bridge; m and s are independently 0 or 1; p, q, r and t are independently 0 or 1; each R6 is independently selected from halogen, cyano, a —NH2 group, —OH, a (C1-C4)alkyl group, —CF3, —C(O)NH2, a —C(O)NH—(C1-C4)alkyl group, —C(O)OH, a —C(O)O—(C1-C4)alkyl group, —SO2NH2, a (C1-C4)alkoxy group, a —O—(C1-C4)alkylene-(C3-C6)cycloalkyl group, a —O—(C3-C6)cycloalkyl group, a —O—(C3-C6)heterocycloalkyl group, a (C3-C6)heterocycloalkyl group, a heteroaryl group and oxo; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
It further relates to the pharmaceutical compositions containing said new compounds.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 261/02 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
C07D 413/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure relates to an assembly of a drug delivery device (1) and an electronic add-on module (2) with a rechargeable electrical energy storage (23) further comprising an electrical generator (3). A first component (30) of the electrical generator (3) is motion-linked to a housing (10, 42) of the drug delivery device (1) and a second component (31) of the electrical generator (3) is motion-linked to an actuation member (11, 12, 41) of the drug delivery device (1) which is rotatable during dose setting and/or dose dispensing. The electrical generator (3) is electrically connectable to the rechargeable electrical energy storage (23) of the electronic module (2). The present disclosure further relates to a method for recharging an electrical energy storage (23) by means of the electrical generator (3).
A fluid transfer device comprises a body comprising a first connecting portion comprising a first fluid channel to fluidically communicate with an interior of a diluent container, a second connecting portion comprising a second fluid channel to fluidically communicate with an interior of a medicament container, a third connecting portion comprising a third fluid channel to fluidically communicate with an interior of a pooling container, and a fourth fluid channel to fluidically communicate with a pump device. A movable part is engaged with and movable relative to the body to transfer the fluid transfer device into one of a first configuration, a second configuration and a third configuration. When in the first configuration, the second fluid channel is fluidically coupled to the third fluid channel, and when in the second configuration, the first fluid channel is fluidically connectable to the third fluid channel.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
An electronic circuit for a drug delivery device includes a communication interface operable to wirelessly communicate with a mobile electronic device of a user and configured to receive an identification signal from the mobile electronic device, a storage operable to store a user specific data record, and a processor operatively connected to the communication interface and to the storage and operable to evaluate the identification signal by comparing the identification signal to the user specific data record, wherein the processor is operable to enable, disable, trigger, or terminate an execution of an electronically implemented function of the electronic circuit based on an evaluation of the identification signal.
The present disclosure relates to a last dose mechanism for use in a drug delivery device (1) and to a drug delivery device (1) with improved sustainability The last dose mechanism substantially comprises a drive sleeve (12) and a nut (17) in threaded engagement with the drive sleeve (12). The drive sleeve (12) and the nut (17) are both made of polypropylene (PP). The nut (17) is a full ring nut.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
The present disclosure relates to compounds of formula (I) (I) wherein n is an integer from 1 to 50; R1 represents a hydrogen atom, a —(C1-C6)alkylene-O—(C1-C6)alkyl group, a —(C1-C6)alkylene-NH—(C1-C6)alkyl group, or a —(C1-C6)alkyl group; R2 represents a —(C1-C6)alkylene- group; R3 represents —O—, —NH— or a —N((C1-C6)alkyl)- group; R4 represents a hydrogen atom, a —(C1-C6)alkyl group or a —(C1-C6)alkoxy group; R5 represents a —(C1-C6)alkylene- group; and R6 represents a -L1-RCG1 group or a —RCG1 group. The present disclosure also relates to conjugates of formula (II), to processes for their preparation, to compositions comprising them and to their therapeutic uses, especially in the prevention and/or in the treatment of a disease or a disorder that may benefit of an activation of the immune system, such as cancers.
The present disclosure relates to compounds of formula (I) (I) wherein n is an integer from 1 to 50; R1 represents a hydrogen atom, a —(C1-C6)alkylene-O—(C1-C6)alkyl group, a —(C1-C6)alkylene-NH—(C1-C6)alkyl group, or a —(C1-C6)alkyl group; R2 represents a —(C1-C6)alkylene- group; R3 represents —O—, —NH— or a —N((C1-C6)alkyl)- group; R4 represents a hydrogen atom, a —(C1-C6)alkyl group or a —(C1-C6)alkoxy group; R5 represents a —(C1-C6)alkylene- group; and R6 represents a -L1-RCG1 group or a —RCG1 group. The present disclosure also relates to conjugates of formula (II), to processes for their preparation, to compositions comprising them and to their therapeutic uses, especially in the prevention and/or in the treatment of a disease or a disorder that may benefit of an activation of the immune system, such as cancers.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
An assembly for a drug delivery device comprising a cap, having a first mark located on the outer surface of the cap, and a device body, having a second mark located on the outer surface of the device body, wherein the first and the second mark form a continuous marking, which extends form the device body to the cap, wherein the cap has first axial position relative to the device body, wherein the cap, when not in the first axial position relative to the device body, can be brought in the first axial position relative to the device body only when the first mark and the second mark form the continuous marking.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
77.
USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING NEUROENDOCRINE CANCERS EXPRESSING CEACAM5
The present disclosure provides methods of treating neuroendocrine cancers using immunoconjugates comprising an antibody that specifically binds hCEACAM5, in particular hCEACAM5.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
78.
POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
79.
CELL-FREE PROTEIN SYNTHESIS SYSTEMS, REACTION MIXTURES FOR SAME, AND METHODS FOR PREPARING PROTEINS
A medicament delivery device comprises a syringe body configured to receive a medicament. The syringe body comprises a distal end and a proximal end, a plunger located in and moveable relative to the syringe body, and a plunger rod assembly extending from the proximal end of the syringe body and configured to move the plunger longitudinally within the syringe body. The plunger rod assembly comprises a plunger barrel and a plunger rod. The plunger barrel contacts the plunger and is configured to cooperate with the plunger rod, which is moveable relative to the plunger barrel from a first position, in which the plunger rod is maximally extended from the plunger barrel, to a second position, in which the plunger rod is in a distal position relative to the first position, to set a specific dose of medicament to be delivered less than the amount of medicament in the syringe body.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for prevention and treatment of
autoimmune, immune-mediated, inflammatory and immunological
diseases and disorders; pharmaceutical preparations for
prevention and treatment of central nervous system and
neurological diseases and disorders; pharmaceutical
preparations for prevention and treatment of rare
autoimmune, immune-mediated, inflammatory, immunological,
central nervous system and neurological diseases and
disorders.
The present disclosure relates to drive unit (3) of a drug delivery device (1) configured for setting and dispensing of a dose of a medicament, the drive unit (3) comprising: a drive unit housing (9) extending along a longitudinal axis (A), the drive unit housing (9) comprising a distal end (4) and a proximal end (5), a first interface (110) provided at the distal end (4), configured to connect with at least one of a container unit (2) and a protective cap (14), the first interface (110) comprising at least a first electrical contact element (111, 112), an electronic unit (70) arranged on or inside the drive unit housing (9), a first elongated device component (40) extending along the longitudinal axis (A), a first electrical conductor path (141) located on or inside the first elongated device component (40), the first electrical conductor path (141) comprising a first path distal end (142) and a first path proximal end (143), wherein the first path proximal end (143) is connected to the electronic unit (70) and wherein the first path distal end (142) is connected to the first electrical contact element (111, 112), wherein the electronic unit (70) is operable to execute an electronically implemented function in response to receive an electric detection signal via the first electrical conductor path (141).
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
83.
PATIENT SELECTION BY PREDICTING TARGET GENE ESSENTIALITY USING MACHINE LEARNING
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for determining whether to select a patient, e.g., to receive a drug that targets a target gene. In one aspect, a method comprises: obtaining gene expression data for a collection of cells from a patient; processing a model input comprising the gene expression data using a machine learning model, in accordance with values of a set of machine learning model parameters, to generate a predicted gene essentiality score for the target gene; and determining whether to select the patient based at least in part on the predicted gene essentiality score for the target gene.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
84.
AN APPARATUS FOR FILLING A MEDICAMENT PREPARATION VIAL
An apparatus for filling a medicament preparation vial with a fixed volume of diluent from a storage container comprises a container, an inlet comprising an inlet spike, and an outlet comprising an outlet spike. An inlet valve located downstream of the inlet spike has a first state allowing fluid communication between the inlet and the chamber, and a second state in preventing fluid communication between the inlet and the chamber. An outlet valve located upstream of the outlet spike has a first state preventing fluid communication between the chamber and the outlet, and a second state allowing fluid communication between the chamber and the outlet. The outlet valve is in the first state when the inlet valve is in the first state, and is moveable from the first state to the second state when the inlet valve is in the first state.
A medical device for use in the preparation of a medicament comprising a tray movable from a first configuration to a second configuration and comprising a first tray portion and a second tray portion. The first tray portion comprises a first retainer to retain a first medicament vial and the second tray portion comprises a second retainer configured to retain a second medicament vial. The first tray portion is pivotable relative to the second tray portion to move the tray from the first configuration to the second configuration. The tray is configured such that the first medicament constituent and the second medicament constituent can be accessed by a user.
A method and medical device (200, 500, 600, 700, 800, 900) for mixing a medicament (106) contained within a medicament vial (210), the medical device comprising a track (220) configured to support the medicament vial, wherein the track comprises an inclined first track section (241) arranged such that, in use, the medicament vial can roll along the track to mix the medicament contained within the medicament vial.
The present disclosure relates to a visual aid for assisting a user in the preparation of a plurality of syringes, the visual aid comprising a plurality of images, wherein each image: is visually representative of a respective syringe of the plurality of syringes; and comprises a respective first visual feature that is representative of a respective first visual feature of the respective syringe and a respective second visual feature that is representative of a respective second visual feature of the respective syringe, the visual features arranged such that they indicate a respective volume of a medicament to be drawn into the respective syringe. The present disclosure also relates to a system comprising a visual aid and a plurality of syringes. The present disclosure also relates to a method of using a visual aid.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.30
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
89.
Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
A vial adapter comprises an adapter body comprising a top wall and a sidewall projecting from the top wall in a longitudinal direction to form a receptacle with a distal side of the top wall. The receptacle is configured to receive at least a portion of a barrel head of an injection vial. A movable part comprises a base part and a spike fixed to the base part. The spike extends through the top wall in a distal direction into the receptacle. The movable part is movable relative to the adapter body from an undeployed position into a deployed position. An interlock is operable to lock the movable part in the undeployed position, and an actuating member extending into the receptacle is coupled to the interlock and operable to unlock the interlock when actuated.
The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A computer-implemented system that generates mutated antibody sequences using machine learning. The system obtains antigen-antibody data defining the amino acid sequences and three-dimensional (3D) structure an antibody-binding region of an antigen and an antigen-binding region of an antibody. The system generates a mutated version of the amino acid sequence of the antigen-binding region by processing partially masked representations of the antigen-antibody data using a design neural network.
The invention relates to a medical device for holding a syringe (1), the medical device comprising: - a holder adapted to receive a syringe body (2) along the axis (X-X), and - a safety sleeve (200) assembled coaxially with the holder so as to be movable between a standby position, in which the safety sleeve (200) is substantially retracted within the holder, and a deployed position, in which the safety sleeve (200) is deployed outwardly of the holder. The safety sleeve (200) comprises a tubular wall (210) including a proximal end part (210P) and a distal end part (210D) which are axially opposed to each other. The safety sleeve (200) further comprises an orientation distal rib (216) extending inward from an inner surface (212) of the distal end part (210D).
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The medical device (10) comprises: - a holder (100) which: - is adapted to receive a syringe body (2), - includes a proximal end part (100P) and a distal end part (100D), - a safety sleeve (200; 1200; 2200; 3200; 4200; 5200) movable between a standby position and a deployed position, wherein the safety sleeve (200; 1200; 2200; 3200; 4200; 5200) comprises a tubular wall (210; 1210; 2210; 3210; 4210; 5210) which is provided with at least one deformation window (211; 1211; 2211; 3211; 4211; 5211) therethrough, and wherein the at least one deformation window (211; 1211; 2211; 3211; 4211; 5211) is provided with a delinearizing feature (212; 1212; 2212; 3212; 4212; 5212).
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
The disclosure relates to a medical device comprising: - a syringe holder (100) adapted to receive at least partially a syringe (1), and - a safety sleeve (200) that is assembled coaxially with the holder (100) and is movable along an axis between a standby position and a deployed position in which the safety sleeve (200) is deployed at least partially outwardly of the holder (100), the safety sleeve (200) having a distal end part (200D) adapted to surround at least an end of a needle (4) of the syringe (1) when the syringe (1) is received in the holder (100) and the safety sleeve (200) is in the deployed position. The safety sleeve (200) comprises an area (204) configured to alter light transmission and to locally reduce a contact surface between the safety sleeve (200) and the holder (100), the area (204) being located in at least part of the distal end part (200D).
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
A vial adapter comprises an adapter body comprising a top wall and a sidewall projecting from the top wall in a longitudinal direction to form a receptacle with a distal side of the top wall. The receptacle is configured to receive at least a portion of a barrel head of an injection vial. A movable part comprises a base part and a spike fixed to the base part. The spike extends through the top wall in a distal direction into the receptacle. An actuating member is mechanically coupled to the movable part, and is movable relative to the adapter body from a start position to an end position along a first direction to induce a distally directed displacement of the movable part relative to the adapter body. The mechanical coupling between the movable part and the actuating member is releasable when the actuating member is in the end position.
The invention provides ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to immune cells, and methods of making and using, such lipids and targeted lipid nanoparticles.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
According to the present disclosure, there is provided an intranasal medicament delivery system comprising a pump dispenser, a medicament container having a central axis, an intranasal nozzle and a connector. The intranasal nozzle comprises first and second nozzle outlets for delivering medicament to a user. The connector is configured to couple the pump dispenser to the medicament container such that the pump dispenser extends from the connector at an angle in the range of about 70 to 110 degrees relative to the central axis of the medicament container. According to the present disclosure, there is also provided a method of preparing an intranasal medicament delivery system.
An adapter for an intranasal nozzle, the adapter having an external surface for resting against a user's nostril and an aperture that extends from a first opening at a first end of the adapter to a second opening at a second end of the adapter. The aperture is configured to receive a conduit of the intranasal nozzle for fixing the adapter to the conduit. Different adapters can be fitted with the same intranasal nozzle to adapt the intranasal nozzle to different users.
According to the present disclosure, there is provided an intranasal medicament delivery device comprising a housing for receiving a medicament container, wherein the medicament container comprises a sealing element. The intranasal medicament delivery device further comprises an intranasal nozzle, a needle configured to fluidly communicate with the medicament container, and an actuator. The actuator is configured such that, when a medicament container is received in the housing, the actuator is operable by a user to move the medicament container from a first position, wherein the medicament container is sealed by the sealing element, to a second position, wherein the needle punctures the sealing element to fluidly communicate with the medicament container. According to the present disclosure there is also provided an intranasal medicament delivery system and a method of operating an intranasal medicament delivery system.
According to the present disclosure, there is provided an intranasal nozzle comprising first and second medicament delivery conduits for fluidly communicating with a fluid flow generator such that, in use, the fluid flow generator is operable to expel medicament from the first and second medicament delivery conduits for delivery to a user. The intranasal nozzle comprises a flexible portion configured to allow for the position of at least one of the first and second medicament delivery conduits to be adjusted. The present disclosure also relates to an intranasal medicament delivery system and to a method of preparing an intranasal medicament delivery system.
